Volume 25, Number 1—January 2019
Synopsis
Clinical and Radiologic Characteristics of Human Metapneumovirus Infections in Adults, South Korea
Hyun Jung Koo, Han Na Lee, Sang-Ho Choi, Heungsup Sung, Hwa Jung Kim, and Kyung-Hyun Do
Table 2
Co-detection of other pathogens and clinical course of patients infected with human metapneumovirus, South Korea*
| Characteristic | Immunocompetent | Solid tumors | SOT | HCT | HM | Steroid use | Total |
|---|---|---|---|---|---|---|---|
| Total | 459 (54) | 174 (20) | 59 (7) | 9 (1) | 58 (7) | 90 (11) | 849 |
| URI | 126 (28) | 68 (39) | 30 (51) | 1 (11) | 20 (35) | 27 (30) | 270 (32) |
| LRD | 333 (73) | 106 (61) | 29 (49) | 8 (89) | 38 (66) | 63 (70) | 579 (68) |
| Ribavirin use | 44 (10) | 22 (13) | 10 (17) | 5 (56) | 23 (40) | 22 (24) | 126 (15) |
| IVIG use | 3 (1) | 0 | 1 (2) | 0 | 1 (2) | 3 (3) | 8 (1) |
| Both ribavirin and IVIG use |
2 (0.4) |
0 |
0 |
0 |
0 |
1 (1) |
3 (0.4) |
| Co-detection of other pathogen, n = 126 | |||||||
| URI | 17 (13) | 18 (26) | 10 (33) | 1 (100) | 10 (50) | 7 (26) | 63 (23) |
| LRD | 72 (21) | 23 (22) | 13 (45) | 1 (13) | 9 (24) | 22 (35) | 140 (24) |
| Bacteria | 48 | 20 | 16 | 1 | 11 | 20 | 116 |
| Virus | 32 | 14 | 7 | 0 | 6 | 5 | 64 |
| Fungi | 3 | 5 | 0 | 1 | 0 | 0 | 9 |
| Bacteria and virus | 6 | 1 | 0 | 0 | 2 | 3 | 12 |
| Bacteria and fungi | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Virus and fungi |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
| Hospital admission | 279 (65) | 98 (56) | 32 (54) | 6 (67) | 35 (60) | 64 (71) | 552 (65) |
| Length of hospital stay, days | 6.0 (4.0–13.0) | 7.0 (4.0–12.0) | 6.0 (4.0–14.0) | 7.0 (5.3–55.3) | 10.5 (5.8–32.5) | 7.0 (4.0–16.0) | 7.0 (4.0–13.0) |
| ICU admission | 42 (9) | 4 (2) | 5 (10) | 1 (11) | 5 (10) | 11 (12) | 68 (8) |
| All-cause mortality rate at 30 d | 16 (3) | 17 (10) | 0 (0) | 2 (22) | 5 (9) | 7 (8) | 47 (6) |
| All-cause mortality rate at 90 d | 18 (4) | 22 (13) | 1 (2) | 3 (33) | 7 (12) | 8 (9) | 59 (7) |
| Overall mortality rate | 42 (9) | 34 (20) | 3 (5) | 4 (44) | 21 (36) | 22 (24) | 126 (15) |
*Values are no. (%) or median (interquartile range) unless otherwise indicated. HCT, hematologic stem cell transplantation; HM, hematologic malignancy; ICU, intensive care unit; IVIG, intravenous immunoglobulin; LRD, lower respiratory tract disease; SOT, solid organ transplants; URI, upper respiratory tract infection.
Page created: December 18, 2018
Page updated: December 18, 2018
Page reviewed: December 18, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.